Esq JD - Oric Pharmaceuticals G Counsel
| ORIC Stock | USD 9.59 0.47 5.15% |
Insider
Esq JD is G Counsel of Oric Pharmaceuticals
| Age | 49 |
| Address | 240 East Grand Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 388 5600 |
| Web | https://www.oricpharma.com |
Oric Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2922) % which means that it has lost $0.2922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4598) %, meaning that it created substantial loss on money invested by shareholders. Oric Pharmaceuticals' management efficiency ratios could be used to measure how well Oric Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.42. In addition to that, Return On Capital Employed is expected to decline to -0.5. The current year's Net Tangible Assets is expected to grow to about 268.5 M, whereas Other Assets are forecasted to decline to about 433.8 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Caroline Godfrey | PepGen | N/A | |
| Maryann Cimino | Pharvaris BV | N/A | |
| MD FACP | AN2 Therapeutics | 76 | |
| Deepika PharmD | Pmv Pharmaceuticals | 47 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Randi MD | Werewolf Therapeutics | 68 | |
| Kenny Ross | Seer Inc | N/A | |
| Peng MD | Pharvaris BV | 46 | |
| Timothy CPA | Werewolf Therapeutics | 66 | |
| , MBA | Molecular Partners AG | 51 | |
| James McArthur | PepGen | 62 | |
| Scott Thomas | Seer Inc | 51 | |
| Annick Deschoolmeester | Pharvaris BV | 51 | |
| Jennifer Cormier | PepGen | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| CPA MBA | Pharvaris BV | 63 | |
| Daniel Hicklin | Werewolf Therapeutics | 60 | |
| Chulani Karunatilake | Werewolf Therapeutics | 64 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 |
Oric Pharmaceuticals Leadership Team
Elected by the shareholders, the Oric Pharmaceuticals' board of directors comprises two types of representatives: Oric Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oric. The board's role is to monitor Oric Pharmaceuticals' management team and ensure that shareholders' interests are well served. Oric Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oric Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, CEO President | ||
| CPA CPA, Chief Officer | ||
| BA BA, CoFounder Board | ||
| Lori Friedman, Chief Officer | ||
| Esq JD, G Counsel | ||
| MS MD, Chief Officer | ||
| Richard Heyman, Independent CoFounder | ||
| Edna Maneval, Senior Development | ||
| Scott Lowe, CoFounder Board | ||
| BA MD, CoFounder Board | ||
| Daniel Iazzetti, VP People |
Oric Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oric Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 407.49 M | ||||
| Shares Outstanding | 70.57 M | ||||
| Shares Owned By Insiders | 9.12 % | ||||
| Shares Owned By Institutions | 90.88 % | ||||
| Number Of Shares Shorted | 11.65 M | ||||
| Price To Book | 2.35 X | ||||
| EBITDA | (109.75 M) | ||||
| Net Income | (100.7 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.